Core Insights - The core viewpoint of the articles highlights the strong performance and growth potential of Ascentage Pharma, particularly driven by its key products, including Nairik and APG-2575, which are positioned to capture significant market opportunities in the oncology sector [1][2]. Group 1: Financial Performance - Ascentage Pharma reported a total revenue of 981 million RMB for the year 2024, representing a 342% year-on-year increase, primarily driven by product sales and external collaboration licensing revenue [1]. - The sales revenue for Nairik reached 241 million RMB, showing a robust year-on-year growth of 52% [1]. Group 2: Product Development and Regulatory Approvals - Nairik is set to be included in the National Medical Insurance Drug List in November 2024, which is expected to provide broader growth opportunities for the company [1]. - Ascentage Pharma is advancing Nairik in three ongoing Phase III clinical trials for various indications, including Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), with one trial approved by the FDA [1]. - The company has established a global rights collaboration with Takeda for Nairik, marking the largest external licensing deal in the domestic small molecule oncology drug sector to date [1]. - The NDA for APG-2575 was accepted by the CDE and is prioritized for review, targeting treatment for refractory/relapsed Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), positioning it as a potential second Bcl-2 inhibitor to market globally [2]. - APG-2575 is currently involved in four global Phase III clinical trials across multiple hematological cancer indications, with one trial also receiving FDA approval [2]. Group 3: Market Position and Future Outlook - The successful IPO on NASDAQ in January 2025 raised 967 million RMB, enhancing the company's financial position for future growth initiatives [3].

Core Insights - Ascentage Pharma's drug olverembatinib has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with low-intensity chemotherapy [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies for unmet medical needs, particularly in hematological malignancies [10][11] - The company is listed on both the Hong Kong Stock Exchange and Nasdaq, indicating its global presence and investment appeal [10] Drug Development and Approval - Olverembatinib is the first third-generation BCR-ABL inhibitor approved in China, with prior approvals for chronic-phase chronic myeloid leukemia (CML-CP) and gastrointestinal stromal tumors [5][12] - The drug has been included in the China National Reimbursement Drug List, enhancing its accessibility to patients [5][12] - A global Phase III study has been cleared for olverembatinib in combination with chemotherapy, positioning it to potentially be the first TKI approved for first-line treatment of Ph+ ALL in China [6] Clinical Significance - The incidence rate of ALL in China is approximately 0.69 per 100,000, with Ph+ ALL representing 20%-30% of adult cases, highlighting a significant unmet medical need [4] - Prior to TKIs, the five-year overall survival rate for Ph+ ALL patients treated with chemotherapy was below 20%, underscoring the importance of new treatment options [4] Regulatory and Market Impact - BTDs are granted to innovative drugs that address serious conditions with no existing treatment, allowing for prioritized development and review processes [3] - The recognition of olverembatinib's clinical value by regulatory authorities is expected to accelerate its development and availability to patients [7]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 21, 2025 Registration No. 333-284064 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASCENTAGE PHARMA GROUP INTERNATIONAL (Exact name of Registrant as specified in its charter) Cayman Islands (State or Other Jurisdiction of Incorporation or Organization) 2834 (Primary Standard Industrial Classification Code Number) Not A ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 27, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ASCENTAGE PHARMA GROUP INTERNATIONAL (Exact name of Registrant as specified in its charter) Cayman Islands (State or Other Jurisdiction of Incorporation or Organization) 2834 (Primary Standard Industrial Classification Code Number) 68 Xinqing Road Suzhou Indust ...